Protalix shares plunge as FDA rejects Gaucher disease drug - Proactiveinvestors (NA)
Links shared publicly online about this topic.
- 484total visits
Protalix shares plunge as FDA rejects Gaucher disease drug - Proactiveinvestors (NA)
Protalix BioTherapeutics' (AMEX:PLX) shares dove nearly 28% on Friday after the company announced the FDA did not approve its new drug being developed with Pfizer for the treatment of Gaucher, a genetic disease that causes fat to build up in the body.
View full resource at proactiveinvestors.com
Most Recently Shared on February 26, 2011 at 3:32 am By:
Protalix shares plunge as FDA rejects Gaucher disease drug - Proactiveinvestors (NA) http://t.co/x5gJmIp
Protalix Shares Plunge As FDA Rejects Gaucher Drug - Update
rttnews.com — “Protalix BioTherapeutics, Inc. (PLX), said Friday the U.S. Food and Drug Administration has rejected a New Drug Application for 'taliglucerase alfa' to treat Gaucher disease, a rare genetic disorder in which fat builds up in the liver, bone marrow and the nervous system.” View full resource at rttnews.com
Most Recently Shared on February 25, 2011 at 6:34 pm By:
Protalix Shares Plunge As FDA Rejects Gaucher Drug - Update - RTT News http://ow.ly/1bviVO
Advertisement
